Pancreatic Cancer|omicsgroup|journal Of Integrative Oncology

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Pancreatic Cancer Scholarly Open Access Journals

Scholarly journals, also referred to as Academic journals. These journals are regularly published journals which are related to a specific academic discipline. Scholarly articles are written by scientist or researchers based on authentic, innovative and native research done by the scholar. Scholars publish their articles to communicate and share their research. These journals are usually understood and accessed by students, academicians or experts from the related field as the content will be highly specific and not grasped and followed by all. These are subjected to peer-review by editorial board members who are highly qualified in that particular field. Lewis et al. addressed the benefit of neoadjuvant therapy for pancreatic adenocarcinoma based on data from the NCDB. They found the frequency of use of neoadjuvant therapy doubled from 6 to 12% of surgical patients from 2006 to 2012. Patients who received neoadjuvant therapy were more likely to be treated at academic centers than those who received surgery first. Those receiving neoadjuvant therapy had statistically significant reductions in post-operative stay (11 vs. 12 days) and 30-day surgical mortality (2.8% vs. 4.9%). Median survival from diagnosis was longer in neoadjuvant therapy group (19.9 months) vs. surgery first group (15.3 months; P<0.001). This benefit was not observed in patients with stage I disease. Long-term survival at 5 years did not differ between the two groups (14% in both groups). This demonstrates that neoadjuvant therapy is becoming increasingly more utilized in clinical practice and may have some benefits in short-term survival and patient selection for surgery, particularly in those with advanced stage disease. Citation: Lewis RS, Drebin JA, Fraker DL, Vollmer CM. A Comprehensive Assessment of Neoadjuvant Therapy for Pancreatic Adenocarcinoma: Results from the National Cancer Database (NCDB). Paper presented at the 48th Annual Meeting of the Pancreas Club; May 2014; Chicago, Illinois, USA.
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger

Last date updated on January, 2021